

# Leah C Katzelnick

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7676083/publications.pdf>

Version: 2024-02-01

40  
papers

4,380  
citations

279487

23  
h-index

288905

40  
g-index

45  
all docs

45  
docs citations

45  
times ranked

8065  
citing authors

#	ARTICLE	IF	CITATIONS
1	Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e42-e51.	4.6	20
2	SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies. <i>Science Translational Medicine</i> , 2022, 14, eabn8543.	5.8	75
3	Beneath the surface: Amino acid variation underlying two decades of dengue virus antigenic dynamics in Bangkok, Thailand. <i>PLoS Pathogens</i> , 2022, 18, e1010500.	2.1	5
4	Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	21
5	A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans. <i>Nature Communications</i> , 2021, 12, 1102.	5.8	40
6	Boosting can explain patterns of fluctuations of ratios of inapparent to symptomatic dengue virus infections. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	8
7	Previous exposure to dengue virus is associated with increased Zika virus burden at the maternal-fetal interface in rhesus macaques. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009641.	1.3	20
8	Adapting Rapid Diagnostic Tests to Detect Historical Dengue Virus Infections. <i>Frontiers in Immunology</i> , 2021, 12, 703887.	2.2	9
9	Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term. <i>Science Translational Medicine</i> , 2021, 13, eabg9478.	5.8	32
10	Antigenic evolution of dengue viruses over 20 years. <i>Science</i> , 2021, 374, 999-1004.	6.0	34
11	SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. <i>Viruses</i> , 2021, 13, 2485.	1.5	23
12	Age-dependent manifestations and case definitions of paediatric Zika: a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 371-380.	4.6	30
13	COVID-19 Vaccines: Should We Fear ADE?. <i>Journal of Infectious Diseases</i> , 2020, 222, 1946-1950.	1.9	55
14	Protective and enhancing interactions among dengue viruses 1-4 and Zika virus. <i>Current Opinion in Virology</i> , 2020, 43, 59-70.	2.6	41
15	Ethics of a partially effective dengue vaccine: Lessons from the Philippines. <i>Vaccine</i> , 2020, 38, 5572-5576.	1.7	43
16	Zika virus infection enhances future risk of severe dengue disease. <i>Science</i> , 2020, 369, 1123-1128.	6.0	171
17	A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. <i>Nature Communications</i> , 2020, 11, 4704.	5.8	775
18	Antibody-Dependent Enhancement of Severe Disease Is Mediated by Serum Viral Load in Pediatric Dengue Virus Infections. <i>Journal of Infectious Diseases</i> , 2020, 221, 1846-1854.	1.9	29

#	ARTICLE	IF	CITATIONS
19	Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas. <i>Scientific Reports</i> , 2019, 9, 16258.	1.6	10
20	Prior dengue virus infection and risk of Zika: A pediatric cohort in Nicaragua. <i>PLoS Medicine</i> , 2019, 16, e1002726.	3.9	130
21	Effects of infection history on dengue virus infection and pathogenicity. <i>Nature Communications</i> , 2019, 10, 1246.	5.8	26
22	Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika. <i>Nature Communications</i> , 2019, 10, 938.	5.8	44
23	Impacts of Zika emergence in Latin America on endemic dengue transmission. <i>Nature Communications</i> , 2019, 10, 5730.	5.8	48
24	Neutralizing Antibody Responses to Homologous and Heterologous H1 and H3 Influenza A Strains After Vaccination With Inactivated Trivalent Influenza Vaccine Vary With Age and Prior-year Vaccination. <i>Clinical Infectious Diseases</i> , 2019, 68, 2067-2078.	2.9	5
25	Dengue genetic divergence generates within-serotype antigenic variation, but serotypes dominate evolutionary dynamics. <i>ELife</i> , 2019, 8, .	2.8	38
26	Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas. <i>Journal of Infectious Diseases</i> , 2018, 218, 536-545.	1.9	124
27	The use of longitudinal cohorts for studies of dengue viral pathogenesis and protection. <i>Current Opinion in Virology</i> , 2018, 29, 51-61.	2.6	14
28	Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. <i>Vaccine</i> , 2018, 36, 3411-3417.	1.7	52
29	Dynamics and determinants of the force of infection of dengue virus from 1994 to 2015 in Managua, Nicaragua. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10762-10767.	3.3	26
30	Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006862.	1.3	93
31	Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. <i>Nature</i> , 2018, 557, 719-723.	13.7	213
32	Dengue: knowledge gaps, unmet needs, and research priorities. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e88-e100.	4.6	153
33	Antibody-dependent enhancement of severe dengue disease in humans. <i>Science</i> , 2017, 358, 929-932.	6.0	800
34	Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes. <i>MBio</i> , 2017, 8, .	1.8	13
35	Immune correlates of protection for dengue: State of the art and research agenda. <i>Vaccine</i> , 2017, 35, 4659-4669.	1.7	81
36	Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 728-733.	3.3	156

#	ARTICLE	IF	CITATIONS
37	Evolutionarily Successful Asian 1 Dengue Virus 2 Lineages Contain One Substitution in Envelope That Increases Sensitivity to Polyclonal Antibody Neutralization. <i>Journal of Infectious Diseases</i> , 2016, 213, 975-984.	1.9	13
38	Dengue viruses cluster antigenically but not as discrete serotypes. <i>Science</i> , 2015, 349, 1338-1343.	6.0	195
39	Burden of Dengue Infection and Disease in a Pediatric Cohort in Urban Sri Lanka. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 132-137.	0.6	35
40	Global spread of dengue virus types: mapping the 70 year history. <i>Trends in Microbiology</i> , 2014, 22, 138-146.	3.5	494